CDT Equity (NASDAQ:CDT) Trading 8.7% Higher – Here’s Why

CDT Equity Inc. (NASDAQ:CDT)’s share price traded up 8.7% during trading on Wednesday . The stock traded as high as $2.27 and last traded at $2.26. 42,358 shares were traded during mid-day trading, a decline of 52% from the average session volume of 89,014 shares. The stock had previously closed at $2.08.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CDT Equity in a research report on Friday, March 27th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

CDT Equity Price Performance

The firm has a market cap of $10.98 million, a price-to-earnings ratio of 0.00 and a beta of 1.60. The stock has a 50-day moving average of $8.80 and a 200-day moving average of $31.62.

CDT Equity Company Profile

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.